MedPharm Gains Olink Certification to Introduce Proteomic Analysis Services
Through this certified status,the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis alongside its human-relevant disease models.
Topical and transdermal specialist CDMO, MedPharm, has announced that it has become an Olink Certified Service Provider (CSP), making it the first organization to hold the certification in the Carolinas and one of only three in the southeastern United States (1). Olink, a Thermo Fisher Scientific company specializing in proteomics and protein biomarker analysis, has developed Proximity Extension Assay (PEA) technology.
With this certification, MedPharm gains access to Olink’s platform, enabling it to deliver targeted, multiplex proteomic analysis, which will allow clients to integrate proteomic data with established disease models using reconstructed and ex vivo human tissues. By integrating protein biomarker data with these models, MedPharm can offer a more detailed understanding of therapeutic activity, biological responses, and potential mechanisms of action in human-relevant systems.
“Becoming an Olink Certified Service Provider extends MedPharm into targeted, multiplex protein biomarker analysis for the first time,” said Jon Lenn, Ph.D., Chief Scientific Officer, MedPharm, in a company press release (1). “We are the only contract research organization with Certified Service Provider status in the Carolinas, and this platform lets us bring that capability to sponsors directly rather than through a third party. This certification is also the first step in a broader plan to expand MedPharm’s capabilities as a contract research organization, supporting clinical trial sample analysis and translational models that support clinical development.”
Olink’s PEA technology uses two DNA-labelled antibodies to recognize the same target protein. When they bind in close proximity, their DNA tags combine to create a protein-specific signal that can be amplified and quantified using quantitative polymerase chain reaction (qPCR) or next-generation sequencing. This enables sensitive, highly multiplexed protein analysis from sample volumes as small as 1 µL, for both absolute and relative measurements across low- and high-abundance targets (2).
MedPharm describes the certification as the first step in a broader expansion of its contract research organization capabilities with planned applications including clinical trial sample analysis and the development of translational models to support clinical development. Operating in the U.S. and UK, and through a partnership network in Belgium, the company provides contract development, research, and manufacturing services for topical and transepithelial products, spanning formulation development, in vitro testing, clinical manufacturing, and commercial-scale production.
References
MedPharm. MedPharm Expands End-to-End Proteomic Analysis Capabilities with Olink Certification. Press Release, Aug. 20, 2026.
Olink. What is PEA?Olink.com (accessed Aug. 24, 2026).